Immunoglobulin G1 (134-Cysteine,228-Valine,242-Phenylalanine,243-Glutamic Acid,339-Serine,362-Cysteine,374-Tryptophan), Anti-(Human Cytotoxic T-Lymphocyte-Associated Protein 4) (Human Monoclonal Medi5752 .Gamma.1-Chain), Disulfide With (122-Cysteine,212-Valine) Human Monoclonal Medi5752 .Lambda.-Chain, (234->231')(237->234')(362->354') Tris(Disulfide) With Immunoglobulin G1 (239-Phenylalanine,240-Glutamic Acid,336-Serine,354-Cysteine,371-Serine,373-Alanine,412-Valine) Anti-(Human Programmed Cell Death Protein 1) (Human-Mus Musculus Monoclonal Medi5752 .Gamma.1-Chain) Disulfide With Human-Mus Musculus Monoclonal Medi5752 .Kappa.-Chain
Renal Cell Carcinoma
Explore 271 assets in Renal Cell Carcinoma →Floatz Rating
CC41/100
Confidence
Indicative
Sponsor
MedImmune LLC
Modality
monoclonal_antibody
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04522323CT.gov A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Renal Cell Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Immunoglobulin G1 (134-Cysteine,228-Valine,242-Phenylalanine,243-Glutamic Acid,339-Serine,362-Cysteine,374-Tryptophan), Anti-(Human Cytotoxic T-Lymphocyte-Associated Protein 4) (Human Monoclonal Medi5752 .Gamma.1-Chain), Disulfide With (122-Cysteine,212-Valine) Human Monoclonal Medi5752 .Lambda.-Chain, (234->231')(237->234')(362->354') Tris(Disulfide) With Immunoglobulin G1 (239-Phenylalanine,240-Glutamic Acid,336-Serine,354-Cysteine,371-Serine,373-Alanine,412-Valine) Anti-(Human Programmed Cell Death Protein 1) (Human-Mus Musculus Monoclonal Medi5752 .Gamma.1-Chain) Disulfide With Human-Mus Musculus Monoclonal Medi5752 .Kappa.-Chain (this asset) | MedImmune LLC | P1 | CC · 41 |
| Sorafenib | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | P4 | BBB |
| Pazopanib | Imbioray (Hangzhou) Biomedicine Co., Ltd. | P4 | BBB |
| Belzutifan | Vall d'Hebron Institute of Oncology | P3 | BBB |
| Cyclosporin A | National Cancer Institute (NCI) | P2 | BB |
| Interferon-Alfa-2A | Central European Society for Anticancer Drug Research | P3 | BB |
| Everolimus | Merck Sharp & Dohme LLC | P4 | BB |
| Atorvastatin | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | P3 | BB |
| Nivolumab | Fred Hutchinson Cancer Center | P4 | BB |
+42 more in the Renal Cell Carcinoma cohort
Other indications for Immunoglobulin G1 (134-Cysteine,228-Valine,242-Phenylalanine,243-Glutamic Acid,339-Serine,362-Cysteine,374-Tryptophan), Anti-(Human Cytotoxic T-Lymphocyte-Associated Protein 4) (Human Monoclonal Medi5752 .Gamma.1-Chain), Disulfide With (122-Cysteine,212-Valine) Human Monoclonal Medi5752 .Lambda.-Chain, (234->231')(237->234')(362->354') Tris(Disulfide) With Immunoglobulin G1 (239-Phenylalanine,240-Glutamic Acid,336-Serine,354-Cysteine,371-Serine,373-Alanine,412-Valine) Anti-(Human Programmed Cell Death Protein 1) (Human-Mus Musculus Monoclonal Medi5752 .Gamma.1-Chain) Disulfide With Human-Mus Musculus Monoclonal Medi5752 .Kappa.-Chain
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Cancer | — | P2 | CCC · 50 |
| Non-Small Cell Lung Carcinoma | — | P1 | CC · 43 |
| Neoplasm | — | P1 | CC · 43 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Immunoglobulin G1 (134-Cysteine,228-Valine,242-Phenylalanine,243-Glutamic Acid,339-Serine,362-Cysteine,374-Tryptophan), Anti-(Human Cytotoxic T-Lymphocyte-Associated Protein 4) (Human Monoclonal Medi5752 .Gamma.1-Chain), Disulfide With (122-Cysteine,212-Valine) Human Monoclonal Medi5752 .Lambda.-Chain, (234->231')(237->234')(362->354') Tris(Disulfide) With Immunoglobulin G1 (239-Phenylalanine,240-Glutamic Acid,336-Serine,354-Cysteine,371-Serine,373-Alanine,412-Valine) Anti-(Human Programmed Cell Death Protein 1) (Human-Mus Musculus Monoclonal Medi5752 .Gamma.1-Chain) Disulfide With Human-Mus Musculus Monoclonal Medi5752 .Kappa.-Chain in Renal Cell Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/immunoglobulin-g1-134-cysteine228-valine242-phenylalanine243-glutamic-acid339-serine362-cysteine374-tryptophan-anti-human-cytotoxic-t-lymphocyte-associated-protein-4-human-monoclonal-medi5752-gamma1-chain-disulfide-with-122-cysteine212-valine-human-monoclonal-medi5752-lambda-chain-234-231237-234362-354-trisdisulfide-with-immunoglobulin-g1-239-phenylalanine240-glutamic-acid336-serine354-cysteine371-serine373-alanine412-valine-anti-human-programmed-cell-death-protein-1-human-mus-musculus-monoclonal-medi5752-gamma1-chain-disulfide-with-human-mus-musculus-monoclonal-medi5752-kappa-chain-renal-cell-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →